Vaccine prepared utilizing human parainfluenza virus type 2 vector

Active Publication Date: 2015-11-19
BIOCOMO +1
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0027]1) The problem of the conventional platform-type inactivated virus vector is that the amount of an antigen transferred per vector is low; thus, antibody production efficiency is low. By contrast, the virus vector of the present invention can contain a quantitatively large amount of an antigenic peptide on the virus particle.
[0028]As described a

Problems solved by technology

For these reasons, the probability of homologous recombination with chromosomal DNA is very small, and the risk of developing cancer due to gene recombination into the chromosome is also small.
On the other hand, in cells or tissues expression of F gene, this vector can do so-called self-replication, but cannot yield an infectious vector.
At the moment, however, there is no report on recombinant live RNA virus vector preparations approved as medicines by the Food and Drug Administration and the European Medicines Agency.
This is presumably because in the case of using recombinant live RNA viruses as vectors, large amounts of viruses and foreign gene products are still produced in infected cells, though safety measures are taken in such a way that pathogenicity is reduced by use of attenuated viruses or non-transmissible vectors are utilized; thus concerns such as their influence on homeostasis or mutations of the foreign genes cannot be dispelled.
Unfortunately, the inactivated vaccines, which are considered to be highly safe, also present safety problems.
In the 1960s, a formalin-inactivated RSV vaccine was developed from RSV belonging to the family Paramyxoviridae, and vaccination with this vac

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine prepared utilizing human parainfluenza virus type 2 vector
  • Vaccine prepared utilizing human parainfluenza virus type 2 vector
  • Vaccine prepared utilizing human parainfluenza virus type 2 vector

Examples

Experimental program
Comparison scheme
Effect test

example 1

Confirmation of Transgene Expression in African Green Monkey Cell (Vero Cell) and Mouse Cell (NIH3T3 Cell) Using hPIV2 / ΔF

[0068]Vero cells or NIH3T3 cells were cultured in a 96-well plate such that the cells became a monolayer at the time of vector infection. hPIV2 / ΔF harboring GFP gene was diluted up to 108 from the undiluted solution. This vector does not yield an infectious vector and therefore exhibits GFP fluorescence only in primarily infected cells. The virus dilutions were each added at 1 / 10 of the amount of each cell culture solution, followed by culture for 3 days.

[0069]As a result, the GFP fluorescence was confirmed in the Vero cells and the NIH3T3 cells when 101 to 107 vector dilutions and 101 to 104 vector dilutions, respectively, were added thereto (FIG. 1).

example 2

Confirmation of the Number of Multiplied Vector Copy in Human and Mouse Dendritic Cell Using hPIV2 / ΔF

[0070](Preparation of Human Dendritic Cells)

[0071]Under the code of ethical conduct, CD14-positive cells were recovered from the peripheral blood of a healthy person. At cell culture days 1, 4, and 7, 50 ng / mL GM-CSF and 25 ng / mL IL-4 were added to the culture solution to culture the cells. The cells cultured for 8 days were infected at a multiplicity of infection (MOI) of 25, 50, or 100 by hPIV2 / ΔF harboring GFP gene. The N gene domain portion of hPIV2 in the cells thus infected for 3 days was subjected to quantitative PCR to measure the number of genome copies.

[0072](Preparation of Mouse Dendritic Cells)

[0073]Under the code of ethical conduct, the bone marrow was recovered from each of the femurs of B57BL / 6 and BALB / c mice and cultured (RPM-1640 medium, 10% FBS) after removal of debris. Every two culture days, the culture solution was replaced with a fresh medium, and GM-C

example 3

Confirmation of Infection Efficiency in Dendritic Cells Using hPIV2 / ΔF

[0075]Under the code of ethical conduct, CD14-positive cells were recovered from the peripheral blood of a healthy person. At cell culture days 1, 4, and 7, 50 ng / mL (in terms of final concentration) GM-CSF and 25 ng / mL (in terms of final concentration) IL-4 were added to the culture solution to culture the cells. The cells cultured for 8 days were infected at a multiplicity of infection (MOI) of 25, 50, or 100 by hPIV2 / ΔF harboring GFP gene.

[0076]Under the code of ethical conduct, the bone marrow was recovered from the femur of B57BL / 6 and cultured (RPM-1640 medium, 10% FBS) after removal of debris. Every two culture days, the culture solution was replaced with a fresh medium, and 20 ng / mL (in terms of final concentration) GM-CSF and 20 ng / mL (in terms of final concentration) IL-4 were added thereto. The cells cultured for 8 days were infected at a multiplicity of infection (MOI) of 25, 50, or 100 by h

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Structureaaaaaaaaaa
Antigenicityaaaaaaaaaa
Login to view more

Abstract

Disclosed are: a virus vector in which a gene encoding an antigenic polypeptide is integrated in human parainfluenza virus type 2 gene, wherein the antigenic polypeptide is expressed in the form of a fusion protein with a viral structural protein; and a method for producing the same. The virus vector of the present invention contains a quantitatively large amount of the antigenic peptide on the virus particle and can efficiently deliver the antigenic polypeptide to a target cell.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner BIOCOMO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products